Establishment Labs (NASDAQ:ESTA) Shares Up 6% - Still a Buy?

Establishment Labs Holdings Inc. (NASDAQ:ESTA - Get Free Report) rose 6% during mid-day trading on Wednesday . The company traded as high as $37.72 and last traded at $37.90. Approximately 171,663 shares traded hands during trading, a decline of 64% from the average daily volume of 471,176 shares. The stock had previously closed at $35.76.

Analyst Upgrades and Downgrades

Several research firms recently commented on ESTA. Needham & Company LLC reaffirmed a "buy" rating and set a $48.00 target price on shares of Establishment Labs in a report on Friday, June 13th. Stephens reaffirmed an "overweight" rating and set a $52.00 target price on shares of Establishment Labs in a research note on Thursday, March 6th. Wall Street Zen upgraded Establishment Labs from a "sell" rating to a "hold" rating in a report on Saturday, June 14th. Finally, BTIG Research began coverage on shares of Establishment Labs in a research report on Friday, May 16th. They issued a "buy" rating and a $62.00 target price for the company. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $52.40.

Establishment Labs Stock Performance

The stock has a market capitalization of $1.09 billion, a PE ratio of -12.18 and a beta of 0.74. The company has a quick ratio of 2.05, a current ratio of 3.36 and a debt-to-equity ratio of 5.72. The stock has a fifty day moving average of $34.85 and a 200-day moving average of $36.95.

Establishment Labs (NASDAQ:ESTA - Get Free Report) last released its quarterly earnings data on Wednesday, May 7th. The company reported ($0.70) earnings per share for the quarter, topping analysts' consensus estimates of ($0.83) by $0.13. Establishment Labs had a negative net margin of 52.34% and a negative return on equity of 196.25%. The company had revenue of $41.38 million for the quarter, compared to analysts' expectations of $41.15 million. During the same quarter last year, the company earned ($0.58) earnings per share. The firm's revenue for the quarter was up 11.3% on a year-over-year basis. Equities analysts anticipate that Establishment Labs Holdings Inc. will post -2.41 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Establishment Labs

Institutional investors and hedge funds have recently modified their holdings of the company. Toronto Dominion Bank purchased a new position in shares of Establishment Labs during the fourth quarter valued at approximately $24,879,000. Brown Advisory Inc. grew its stake in shares of Establishment Labs by 23.1% in the fourth quarter. Brown Advisory Inc. now owns 2,338,369 shares of the company's stock valued at $107,729,000 after buying an additional 438,057 shares in the last quarter. Capital Research Global Investors lifted its position in Establishment Labs by 29.3% during the 4th quarter. Capital Research Global Investors now owns 1,911,525 shares of the company's stock worth $88,064,000 after acquiring an additional 433,484 shares in the last quarter. Voya Investment Management LLC boosted its holdings in Establishment Labs by 7,249.5% in the 4th quarter. Voya Investment Management LLC now owns 408,262 shares of the company's stock worth $18,809,000 after acquiring an additional 402,707 shares during the period. Finally, Millennium Management LLC lifted its holdings in Establishment Labs by 96.9% in the 4th quarter. Millennium Management LLC now owns 711,691 shares of the company's stock worth $32,788,000 after buying an additional 350,213 shares in the last quarter. Institutional investors and hedge funds own 72.91% of the company's stock.

Establishment Labs Company Profile

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.